Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Posted on December 16th, 2015 by Joyce de Langen in Pharmacovigilance
Limitations of clinical trials and traditional post-marketing sources of safety information.
Due to limitations of pre-marketing clinical trials, there isn’t much information available once a medicinal product is authorized for marketing. (more…)
Posted on October 30th, 2015 by Thibault Geoui in Chemistry
Antipsychotics have complex pharmacological profiles and adverse events are common with long-term use. New or optimized drugs with better safety profiles are desirable. The best way to get information on a new compound that has potential as an antipsychotic is to use in silico profiling to compare it to existing drugs, as described in this new paper.